Johnny Appleseed brand announces new hard cider
ST. LOUIS — Johnny Appleseed, a new brand from Anheuser-Busch, announced that its Johnny Appleseed Hard Apple Cider will debut on store shelves beginning April 7. More than 750 consumers from the United States, Canada and the United Kingdom help to co-design the brand — from taste profile to packaging, the company said.
“Cider is hotter than ever right now, and Johnny Appleseed is an exciting new entry to the category” said Adam Oakley, VP high-end at Anheuser-Busch. “We have something very special here — the perfect balance of sweetness and intensity with a refreshing crisp apple bite. It’s unlike any other hard cider on the market today.”
Johnny Appleseed Hard Apple Cider will be available in 12-oz. glass bottles with a twist-off cap in six-packs and 12-packs. It will also be sold individually in 16-oz. and 25-oz. cans.
Remodeled Hy-Vee store to feature drive-through pharmacy
OMAHA, Neb. — Westwood Financial, a national owner-operator of shopping centers, has announced the expansion and remodel of a Hy-Vee supermarket at its Applewood Centre here.
The current 60,000-sq.-ft. store will be expanded by 10,500 sq. ft. to accommodate a pharmacy drive-thru, in-store restaurant and wine & spirits store.
“It has been a pleasure to work with Hy-Vee to accommodate this expansion,” stated Kenneth Loughran, SVP Westwood Financial. “The upgraded and remodeled store will not only give Hy-Vee a more contemporary look inside and out, but it also will drive additional traffic to the center, which is a benefit for existing tenants and an incentive to business owners interested in starting or expanding businesses at Applewood.”
Hy-Vee operates 236 stores throughout the Midwest.
Mallinckrodt completes acquisition of Cadence Pharmaceuticals
DUBLIN — Mallinckrodt, a specialty pharmaceuticals company, announced the completion of its acquisition of Cadence Pharmaceuticals for approximately $1.4 billion.
The acquisition adds Ofirmev (acetaminophen) injection to Mallinckrodt’s roster of brands and its specialty pharmaceuticals portfolio of controlled substance specialty generics.The drug is used to manage mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics and the reduction of fever, the company said. Ofirmev also will expand Mallinckrodt presence in the U.S. hospital channel.
“We are excited by the opportunities provided by Ofirmev, which will significantly expand Mallinckrodt’s ability to serve U.S. hospitals,” said Mark Trudeau, resident and CEO of Mallinckrodt. “As anticipated, the transaction was straightforward, closed quickly, and we are planning for a rapid and successful integration, which we expect to be completed by the beginning of September. We believe this accelerated integration will provide greater clarity and direction for the employees joining us, and ensure that the merger of Ofirmev and the transition of the hospital team into Mallinckrodt is smooth and best serves our customers.”